Navigation Links
Efavirenz in Medical News

Merck Cuts Price of Efavirenz for Developing Countries Again

Merck & Co has cut the price of efavirenz 600mg tablets (Stocrin) for developing countries that qualify for its access programme//, the company announced yesterday. It is the second price cut in a year, and crucially, it will make the branded version of efavirenz cheaper than a generic impor...

Brazilian President Silva Issues Compulsory License for Merck's Antiretroviral Efavirenz

Brazilian President Luiz Inacio Lula da Silva on Friday issued a compulsory license to produce a lower-cost, generic version of Merck's antiretroviral Efavirenz, the AP/Forbes reports. World Trade Organization regulations allow governments to declare a "national emergency" and issue compul...

HIV integrase inhibitor effective for patients beginning antiretroviral treatment

...reached that goal, compared with 82 percent of the efavirenz group. Half the raltegravir group reached the e...k four, compared with less than 20 percent for the efavirenz group. In addition, the raltegravir group encounte...t of Health and Human Services currently recommend efavirenz or a protease inhibitor, in combination with tenof...

Tools for more accurate dosage of drugs against HIV/AIDS and malaria

...om Zimbabwe with HIV/AIDS, and showed that a reduction in the daily dose of efavirenz from 600 mg to 400 mg can reduce the risk of undesired effects in those aff...effects of anti-HIV/AIDS drugs. Calculations showed that treatment in which efavirenz was combined with other pharmaceutical substances was more effective than t...

Study Supports Popular HIV Drug Regimen

...hers found that the combination of a drug known as efavirenz (also known as Sustiva) plus two NRTI drugs did a ...e-third of those who took lopinavir-ritonavir plus efavirenz -- two drugs instead of the usual three -- and in...'s a simpler treatment for patients," she said. efavirenz isn't for everyone, Riddler cautioned. "A certain ...

Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

... $78 million in the same period in 2006. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S. and Canada with Gilead Sciences, Inc. -- S...

Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a p...

Brazil Government New Health Offer

...tributing free drugs and condoms in his new AIDS program angered the international drug company Merck. Merck offered to cut the price of its AIDS drug efavirenz to about $1 per pill but Temporao decided to break Merck's patent and buy a cheaper substitute from India. His blunt style is reaching beyond ...

Thailand Unfazed As US Worries Over Copyright Violations

...emporarily suspend patent protections on medicines to safeguard public health. Thailand has issued compulsory licenses for AIDS drugs Kaletra and efavirenz and popular heart disease medicine Plavix. The government plans to import generic versions of the drugs from India, but could also choose to manufactu...

Brazil Opts for Indian Drugs Bypassing Merck

...S pharmaceutical giant Merck's patent on AIDS drug efavirenz and opted for a cheaper generic alternative from ... Brazil will be able to import generic versions of efavirenz from three companies in India - and the price for ...ating with Merck for three years to bring down the efavirenz price. Lula had criticized Merck for charg...
Efavirenz in Medical Technology

Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "The data presented this week demonstrate the value of...

Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference

... President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in t...

Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008

...g studied in phase III trials, achieved an undetectable viral load (<50 HIV-1 RNA copies/mL) at week 96 compared with 71 percent of patients receiving efavirenz (EFV). Of patients receiving the 75 mg and 150 mg doses of TMC278, 72 percent and 71 percent achieved an undetectable viral load, respectively. "NNR...

Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV

...V-1, are now recruiting patients. The global trials will compare the efficacy, safety and tolerability of TMC278 (25 mg) once daily oral tablet versus efavirenz (EFV), each coadministered with a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs), in treatment-naive HIV-...

Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potenti...

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

...vantages. These include: the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen;...

Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus

...candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieves trough levels in human...t a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R), Bristol-Myers Squibb); a high genetic barrier to resistance; t...

IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients

...activity against established NNRTI-resistant clinical isolates. Compared to efavirenz (Sustiva(R)), the emergence of IDX899-resistant HIV-1 isolates was slower a...ted in-vitro with IDX899 were different from those selected with efavirenz. efavirenz appeared to be active against IDX899 resistant viruses and IDX899 remained ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

...of their first antiretroviral treatment regimen. efavirenz is marketed by Bristol-Myers Squibb Company (NYSE:...nd, Germany, Italy, Spain and the United Kingdom). efavirenz is commercialized by Merck & Co., Inc, through its...s-like behavior, but it could not be determined if efavirenz was the cause. Patients with serious psychiatric a...
Efavirenz in Biological News

Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults

...V-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less l...re significantly less likely than those started on efavirenz to achieve high treatment adherence." Nachega, ...erse transcriptase inhibitor such as nevirapine or efavirenz in resource limited settings. Nearly 67 percent of...
Efavirenz in Biological Technology

Monogram Announces 2008 Third Quarter Financial Results

...assay demonstrated an overall improvement in Selzentry efficacy relative to efavirenz (the control arm of the trial). In the new retrospective analysis of the ME...duals achieved HIV-1 RNA <50 copies/mL at week 48 in both the Selzentry and efavirenz arms of the study. "Given the efficacy of existing first line treatments,...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... $82 million in the same period in 2007. Total revenue for the SUSTIVA(R) Franchise includes sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in the combination therapy ATRIPLA(TM), which is sold through a joint venture in the U.S., Canada and Europe with Gilead Sciences, ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

...dvantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (SUSTIVA(R)) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

...e properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a ...
Other Tags
(Date:7/13/2014)... July 13, 2014 A Massachusetts couple ... the cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... story to federal regulators, as they presented poignant testimony ... & Drug Administration (FDA) advisory panel meeting convened to ... to the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm ...
(Date:7/13/2014)... York, New York (PRWEB) July 13, 2014 ... lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson ... litigation’s second bellwether trial, which is expected to get ... Order issued in the U.S. District Court, Southern District ... Conference will be held on August 7, 2014 at ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. ... extremely beautiful. Recently, the company has announced its new ... What’s more, all these outfits are available at discounted ... Additionally, the supplier is now offering similar discounts for ... it has many other designs for sale, including flower ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review recently updated ... what to do to eliminate the root cause of ... review that readers can easily learn what foods to avoid ... Vkool also informs in its Kidney Disease Solution review that ... naturally. The book consists of a collection of natural remedies ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 ... Ken Woolcott, who commented, “As a parent of a ... the underserved need in the Seattle community for contemporary ... will provide an important alternative to students and families ... the best practices and environment for special education. We ...
Breaking Medicine News(10 mins):Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
(Date:7/11/2014)... SEATTLE, WASH. July 11, 2014 Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
(Date:7/11/2014)... the marginal division of the striatum is also ... impact degree of substance P in the striatal ... Yu and his team, College of Biophotonics, South ... that substance P receptor, neurokinin 1 was highly ... of normal rats. Unilateral or bilateral injection of ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
Other Contents